Pandemic Is Likely to Alter Autoimmune Disorder Care Delivery

As a result of the COVID-19 pandemic, patients with autoimmune disorders who depend on caregiver-administered drugs face serious challenges to their safety, according to a recent analysis published by Avalere Health. Many patients who need to visit a clinical site to receive treatment for autoimmune disorders are confronted with a difficult choice: go out in public to face the danger of a virulent, fast-spreading pandemic for which they are at acute risk, or stay home and go without their medication.

“[Immunocompromised] patients are experiencing this maybe more acutely than any of us,” Lance Grady, a managing director at Avalere and one of the authors of the white paper, tells AIS Health. “For a patient to have to sit in their home and have a telehealth engagement with their provider, that’s a new experience. Then for a patient to go through a workup with their provider and understand what other therapeutic alternatives might be available, or what the next steps are in care — typically these are interventions that require a patient to ambulate. A patient would then have to say, ‘Is it safe for me to go out there?’”

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today